Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Neurontin
Neurontin
Almeida, I., & Galarza de López, N. (2014). Cuadro Nacional de Medicamentos Básicos y
Registro Terapéutico. (I. Almeida & N. Galarza de López, Eds.) (9a ed.). Quito:
https://doi.org/10.1001/jama.289.4.454
https://en.wikipedia.org/wiki/List_of_off-label_promotion_pharmaceutical_settlements
Colquhoun, D. (2011). Publish-or-perish: Peer review and the corruption of science | David
https://www.theguardian.com/science/2011/sep/05/publish-perish-peer-review-science
Department of Justice. (2004). Press Release: Warner-Lambert to Pay $430 Million to Resolve
Criminal & Civil Health Care Liability Relating to Off-Label Promotion. Washington,
https://www.justice.gov/archive/opa/pr/2004/May/04_civ_322.htm
Foley, S. (2012, julio 3). GlaxoSmithKline pays $3bn for illegally marketing depression drug.
https://www.independent.co.uk/news/business/news/glaxosmithkline-pays-3bn-for-
illegally-marketing-depression-drug-7904555.html
Gigerenzer, G., Gaissmaier, W., Kurz-Milcke, E., Schwartz, L. M., & Woloshin, S. (2008).
Helping Doctors and Patients Make Sense of Health Statistics: Toward an Evidence-Based
Society. Psychological Sciene in the Public Interest, 8(2), 53–96.
https://doi.org/10.1111/j.1539-6053.2008.00033.x
Gigerenzer, G., Wegwarth, O., & Feufel, M. (2010). Misleading communication of risk. BMJ
Hodgekiss, A., & Spencer, B. (2016). How Big Pharma greed is killing tens of thousands
http://www.dailymail.co.uk/health/article-3460321/How-Big-Pharma-greed-killing-tens-
thousands-world-Patients-medicated-given-profitable-drugs-little-proven-benefits-leading-
doctors-warn.html
Kaplan, R. M., & Irvin, V. L. (2015). Likelihood of null effects of large NHLBI clinical trials
https://doi.org/10.1371/journal.pone.0132382
partir de https://www.forbes.com/sites/erikakelton/2013/07/29/is-big-pharma-addicted-to-
fraud/#487b1db815fe
Kendrick, M. (2015). Study 329 – where the hell is the outrage? Recuperado el 26 de mayo de
the-outrage/
Kim, T. (2018). Goldman asks: “Is curing patients a sustainable business model?” Recuperado
curing-patients-a-sustainable-business-model.html
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T.
https://doi.org/10.1371/journal.pmed.0050045
Kirsch, I., & Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of
Landefeld, C. S., & Steinman, M. A. (2009). The Neurontin Legacy — Marketing through
https://doi.org/10.1056/NEJMp0808659
Malhotra, A. (2018). Killing For Profit - at the European Parliament! Bélgica: YouTube.
Ornstein, C., & Thomas, K. (2018, diciembre). Prominent Doctors Aren’t Disclosing Their
Industry Ties in Medical Journal Studies. And Journals Are Doing Little to Enforce Their
doctors-industry-ties-disclosures-medical-journal-studies
rott_b_8861526.html
Rein, B. W., & Barry, J. E. (2011). Government Regulation of Commercial Speech After Sorrell
v. IMS Health, Inc. Pharmaceutical Law & Industry Report, 9, 2012–2014. Recuperado a
partir de
https://web.archive.org/web/20180529132635/https://www.wileyrein.com/resources/docu
ments/SorrellArticle1.pdf
Rothman, D. J., Blumenthal, D., Chimonas, S. C., Cohen, J. J., Kassirer, J. P., Kimball, H., &
Naughton, J. (2006). Health Industry Practices That Create A Policy Proposal for
Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S. (2006). Review Narrative
Review: The Promotion of Gabapentin: An Analysis of. Annals of Internal Medicine, 145,
284–293. https://doi.org/10.7326/0003-4819-145-4-200608150-00008
Thomas, K., & Ornstein, C. (2018, diciembre 8). Doctors and Disclosures. New York Times.
conflicts-of-interest.html
Ziai, K., Pigazzi, A., Smith, B. R., Nouri-Nikbakht, R., Nepomuceno, H., Carmichael, J. C., …
Jafari, M. D. (2018). Association of Compensation From the Surgical and Medical Device
Industry to Physicians and Self-declared Conflict of Interest. JAMA Surgery, 92868, E1–
E6. https://doi.org/10.1001/jamasurg.2018.2576